Regeneron Stock In The News

Regeneron Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Regeneron earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
There is far too much social signal, news, headlines, and media speculation about Regeneron Pharmaceuticals that is available to investors today. That information is available publicly through Regeneron media outlets and privately through word of mouth or via Regeneron internal channels. However, regardless of the origin, that massive amount of Regeneron data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Regeneron Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Regeneron Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Regeneron Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Regeneron Pharmaceuticals alpha.

Regeneron Largest EPS Surprises

Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2004-07-26
2004-06-30-0.3-0.260.0413 
1999-10-28
1999-09-30-0.2-0.160.0420 
2008-11-04
2008-09-30-0.32-0.270.0515 
2000-07-27
2000-06-30-0.13-0.080.0538 
1997-08-01
1997-06-30-0.21-0.160.0523 
2012-02-13
2011-12-31-0.6-0.540.0610 
View All Earnings Estimates

Regeneron Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Regeneron Pharmaceuticals Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
nasdaq News
30th of June 2022
5 Top Biotech Stocks To Watch In July 2022 - Nasdaq
at www.nasdaq.com 
marketwatch News
22nd of June 2022
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors ...
at www.marketwatch.com 
news
8th of June 2022
Sanofi and Regeneron score pediatric nod for Dupixent, satisfying the itch for young kids ...
at www.fiercepharma.com 
Macroaxis News
3rd of June 2022
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subje...
at MacroaxisInsider 
Yahoo News
31st of May 2022
Regeneron Completes Acquisition of Checkmate Pharmaceuticals - Yahoo Finance
at finance.yahoo.com 
nasdaq News
23rd of May 2022
FDA Approves Regenerons Dupixent To Treat Eosinophilic Esophagitis - Nasdaq
at www.nasdaq.com 
marketwatch News
20th of May 2022
ADRs End Higher, Leju Holdings and Sanofi Trade Actively - MarketWatch
at www.marketwatch.com 
Macroaxis News
17th of May 2022
Sale by Murphy Andrew J of 352 shares of Regeneron Pharmaceuticals
at MacroaxisInsider 
Macroaxis News
5th of May 2022
Sale by Murphy Andrew J of 465 shares of Regeneron Pharmaceuticals
at MacroaxisInsider 
benzinga news
2nd of May 2022
Heres Why This Analyst Cut Price Target On Regeneron - Benzinga - Benzinga
at www.benzinga.com 
news
5th of April 2022
Sale by Leonard Schleifer of 4461 shares of Regeneron Pharmaceuticals
at pulse2.com 

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Regeneron Pharmaceuticals Implied Volatility

    
  22.06  
Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Additionally, take a look at Regeneron Pharmaceuticals Backtesting and Regeneron Pharmaceuticals Hype Analysis. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.15
Market Capitalization
65.6 B
Quarterly Revenue Growth YOY
0.17
Return On Assets
0.26
Return On Equity
0.5
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
REGN
 Stock
  

USD 595.40  4.27  0.72%   

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Regeneron and other traded companies coverage. We help investors stay connected with Regeneron headlines for the 1st of July to make an informed investment decision based on correlating the impacts of news items on Regeneron Stock performance. Please note that trading solely based on the Regeneron Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses. Net Income Common Stock is expected to rise to about 869.6 M this year.
  
Refresh
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Regeneron Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Additionally, take a look at Regeneron Pharmaceuticals Backtesting and Regeneron Pharmaceuticals Hype Analysis.
Regeneron Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Regeneron Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Regeneron Pharmaceuticals noise-free hype analysis.